Barinthus Biotherapeutics PLC
BRNS1.325USD
-0.075-5.36%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
53.45MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Barinthus Biotherapeutics PLC Unternehmen
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases and autoimmunity. Its pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells and guide them towards a healthy balance. It is focused on developing two key product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease.
Unternehmensinformationen
BörsenkürzelBRNS
Name des UnternehmensBarinthus Biotherapeutics PLC
IPO-datumApr 30, 2021
CEOMr. William J. (Bill) Enright
Anzahl der mitarbeiter105
WertpapierartDepository Receipt
GeschäftsjahresendeApr 30
AddresseUnit 6-10, Zeus Building, Rutherford Avenue
StadtDIDCOT
BörseNASDAQ Global Market Consolidated
LandUnited Kingdom
PostleitzahlOX11 0DF
Telefon441865818808
Websitehttps://www.barinthusbio.com/
BörsenkürzelBRNS
IPO-datumApr 30, 2021
CEOMr. William J. (Bill) Enright
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
638.44K
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
48.26K
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
10.51K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
3.00K
--
Dr. Joseph C. Scheeren
Dr. Joseph C. Scheeren
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Principal Financial Officer, Director
Chief Executive Officer, Principal Financial Officer, Director
--
--
Ms. Karen T. Dawes
Ms. Karen T. Dawes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alex Hammacher
Dr. Alex Hammacher
Non-Executive Director
Non-Executive Director
--
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Alex Hammacher
Dr. Alex Hammacher
Non-Executive Director
Non-Executive Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
638.44K
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
48.26K
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
10.51K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
3.00K
--
Dr. Joseph C. Scheeren
Dr. Joseph C. Scheeren
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Principal Financial Officer, Director
Chief Executive Officer, Principal Financial Officer, Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, Jul 4
Aktualisiert: Fri, Jul 4
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Oxford Science Enterprises PLC
21.81%
M&G Investment Management Ltd.
12.88%
Cawood (Frank Wayne)
8.39%
Alphabet, Inc.
3.75%
HSG Holding Ltd.
3.52%
Other
49.64%
Aktionäre
Aktionäre
Anteil
Oxford Science Enterprises PLC
21.81%
M&G Investment Management Ltd.
12.88%
Cawood (Frank Wayne)
8.39%
Alphabet, Inc.
3.75%
HSG Holding Ltd.
3.52%
Other
49.64%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
25.56%
Investment Advisor
18.09%
Individual Investor
13.54%
Corporation
0.92%
Investment Advisor/Hedge Fund
0.53%
Endowment Fund
0.30%
Hedge Fund
0.15%
Research Firm
0.04%
Other
40.87%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
40
23.85M
59.13%
+716.00K
2025Q1
41
23.85M
60.03%
+745.95K
2024Q4
40
24.08M
59.87%
+1.54M
2024Q3
37
20.03M
50.21%
-349.60K
2024Q2
38
20.26M
51.12%
-213.80K
2024Q1
38
20.04M
50.62%
-468.31K
2023Q4
42
19.97M
51.73%
-616.84K
2023Q3
45
19.96M
51.78%
-695.67K
2023Q2
52
20.10M
52.29%
-1.03M
2023Q1
51
20.44M
53.30%
-692.87K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Oxford Science Enterprises PLC
8.80M
21.81%
--
--
Apr 14, 2025
M&G Investment Management Ltd.
5.20M
12.88%
--
--
Mar 31, 2025
Cawood (Frank Wayne)
3.38M
8.39%
+1.04M
+44.47%
Dec 31, 2024
Alphabet, Inc.
1.51M
3.75%
--
--
Mar 31, 2025
HSG Holding Ltd.
1.42M
3.52%
--
--
Mar 31, 2025
Enright (William)
1.24M
3.08%
--
--
Apr 14, 2025
DC Funds, LP
642.20K
1.59%
--
--
Mar 31, 2025
Lynn (Geoffrey)
638.44K
1.58%
+638.44K
--
Dec 17, 2024
Gilead Sciences Inc
369.86K
0.92%
-250.50K
-40.38%
Mar 31, 2025
Johns Hopkins University
122.24K
0.3%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
